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The question then arose as to whether there was any difference 
amongst the different antihypertensive drugs.
The MRC trial was one of the few trials to compare the effects 
of two different drugs – benzofluazide, a diuretic, and propranolol, 
a beta-blocker. They reported that “…neither of the two drug regi-
mens had any clear overall advantage over the other…” and yet “…
the diuretic was perhaps better than the beta-blocker in preventing 
stroke”. The latter observation was not confirmed however, in a 
comparison of 14 unconfounded randomized trials of antihyper-
tensive drugs – with mainly diuretics and beta-blockers (Collins 
et al., 1990). They concluded that “…no consistent differences in 
stroke…were demonstrated in trials….”
The fact that lowering blood pressure with a wide range of drugs 
with very different mechanisms of action has a beneficial effect on 
stroke occurrence, would argue that the important factor is lower-
ing blood pressure rather than the pharmacological way in which 
this is done (Figure 1). This is backed up by epidemiological data 
showing that stroke occurrence, survival and recurrence are all 
affected by high blood pressure (Sacco et al., 1982).
InhIbItIon of the RAAS And StRoke – bAckgRound 
StudIeS
Although drugs such as diuretics and beta-blockers do impact on 
the renin–angiotensin–aldosterone system (RAAS), their effect on 
blood pressure is not primarily related to their effects on the RAAS.
Drugs that lower blood pressure by blocking the RAAS became 
available in the 1980s.
When the first inhibitor of the RAAS that was reasonably well 
tolerated – captopril an inhibitor of the angiotensin I convert-
ing enzyme (ACEI) – began to be more and more widely used 
in the early 1980s, several questions were asked. Were ACEIs 
safe  drugs  compared  to  the  well-known  conventional  treat-
ment available at the time (with diuretics and beta-blockers)? If 
dRug-Induced loweRIng of hIgh ARteRIAl blood 
pReSSuRe And cARdIovASculAR moRbI-moRtAlIty – 
exIStence of A pRefeRentIAl effect on the ceRebRAl 
cIRculAtIon?
Once  antihypertensive  drugs  that  were  reasonably  well  tolerated 
became available in the 1950s and 1960s, it became possible to evalu-
ate whether chronically lowering high blood pressure [at first from 
moderately to severely elevated diastolic blood pressure (DBP) levels of 
90–114 mmHg], would lower cardiovascular morbi-mortality (Freis, 
1995). Thus the Veterans’ Administration (VA) cooperative study, 
one of the first randomized, placebo-controlled, double blind, multi-
institutional clinical trials of antihypertensive treatment demonstrated 
that target organ damage was lowered by 50% in treated groups and 
furthermore that the beneficial effect on stroke was greater than that 
on heart attacks (Veterans’ Administration Cooperative Study Group 
on Antihypertensive Agents, 1970). This “preferential” effect of anti-
hypertensive agents on the cerebral circulation was also seen in the 
Australian Therapeutic Trial in Mild Hypertension (The Management 
Committee, 1980) in which there were fewer cerebrovascular events in 
the treated group – but little overall difference in ischemic heart disease.
A similar result was obtained in the MRC trial (The Medical 
Research Council Working Party, 1985) on the treatment of mild 
hypertension (DBP 90–109 mmHg). In this trial stroke was lower 
on active treatment but there was no difference in overall rates of 
coronary events. Thus from an early date it appeared that antihy-
pertensive treatment could have a beneficial effect on the cerebral 
circulation – and that this effect was (perhaps) greater than that 
on other circulations such as the coronary.
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morbi-mortality as large as (or greater than) that obtained with 
conventional therapy?
The Nordic Captopril Prevention Project (CAPP; Hansson et al., 
1999) was one of the few trials comparing “newer” to “older” treat-
ment, viz captopril with conventional antihypertensive therapy 
with diuretics and beta-blockers. The two regimens did not dif-
fer in preventing cardiovascular morbi-mortality excepting that 
stroke was apparently more common with captopril. The authors 
suggested that the difference in stroke risk “…is probably due to 
the lower levels of blood pressure obtained initially in previously 
treated people randomized to conventional therapy.” Again in this 
trial blood pressure appeared to be the predominant factor.
Albeit in other trials the results on the relative risk for strike 
were in favor of the ACEI. Thus in the HOPE trial (The Heart 
Outcomes  Prevention  Evaluation  (HOPE)  Study  Investigators, 
2000b) using the ACEI ramipril, the relative risk for stroke (0.68, 
P < 0.01) was in favor of the ACEI. The authors argued that the 
beneficial effect of ramipril was linked to inhibition of the RAAS or 
to some other effect of ramipril unrelated to lowering of blood pres-
sure. In a related study – the microalbuminuria, cardiovascular and 
renal outcomes (MICRO) HOPE sub-study (The Heart Outcomes 
Prevention Evaluation (HOPE) Study Investigators, 2000a), the risk 
reduction of cardiovascular events was again greater than that to 
be expected from the difference in blood pressure, suggesting that 
ramipril, and perhaps ACEIs in general, have a “protective” effect 
on the vascular wall.
This could be brought about by inhibition of the RAAS and/
or an increase in bradykinin (Unger, 2002). Regarding the latter 
however, it should be pointed out that stimulation of B2 receptors 
may produce brain damage (Schöller et al., 2011) and so offset 
any beneficial effect obtained with bradykinin-induced cerebral 
vasodilatation.
Following the establishment of ACEIs as effective and safe anti-
hypertensive drugs with potential protective effects on the vas-
culature, angiotensin II type 1 receptor antagonists (ARB) were 
introduced. Losartan was the first ARB available clinically and in 
the LIFE trial (Dahlöf et al., 2002) its cardiovascular effects were 
compared to those of the beta-blocker, atenolol. The conclusion 
was that “…losartan prevents more cardiovascular morbidity…
than atenolol for a similar reduction in blood pressure”. Once again 
a trial that showed a beneficial effect of RAAS blockade.
Debate continues over whether a certain mechanism of action 
(in this case blockade of the RAAS) confers additional beneficial 
impact on cardiovascular morbi-mortality over and above the 
reduction in blood pressure (Figure 1). Potential mechanisms 
involved – especially for ARBs – have been discussed in several 
reviews (Chrysant, 2005; Thöne-Reineke et al., 2006). These include 
the possibility that blockade of the angiotensin II type 1 recep-
tor (vasoconstrictor) by ARB treatment, “uncovers” angiotensin 
II stimulation of the vasodilator angiotensin II type 2 receptor. 
Our group has shown that in the presence of the ARB, telmisartan, 
angiotensin II produces dilatation of cerebral arterioles in an animal 
model of hypertension, the spontaneously hypertensive rats (SHR; 
Vincent et al., 2005; Figure 2).
InhIbItIon of the RAAS And StRoke – new dIRectIonS
uSe of combInAtIonS of exIStIng dRugS
Bi- and tri-therapy regimens have been used in the treatment of 
high arterial blood pressure for several decades. Regimens generally 
use drugs that act on different pharmacological pathways. Thus 
ACEIs or ARBs that block the RAAS are combined with diuretics 
that lower blood pressure by causing the body to rid itself of excess 
fluids and sodium (whilst at the same time activating the RAAS).
An original approach using combinations of drugs that act on 
the same pharmacological system has been proposed (Unger, 2002). 
Treatment with an ACEI may not completely block the RAAS as 
angiotensin I levels may rise due to interruption of the negative 
feedback control of renin release by angiotensin II, dissociation of 
the ACEI from the active sites of the enzyme and/or production of 
angiotensin II by other enzymatic pathways such as those involving 
chymase (Menard et al., 1997). When a combination of low doses 
of enalapril (ACEI) and losartan (ARB) was given to SHR, a syn-
ergistic effect on blood pressure and left ventricular hypertrophy 
was observed and this was attributed to more effective inhibition 
of the RAAS (Menard et al., 1997).
In the ONTARGET clinical trial (The ONTARGET Investigators, 
2008) telmisartan (ARB) was combined with ramipril (ACEI) again 
on the basis that an ACEI does not completely block the RAAS 
so addition of an ARB may be beneficial. However no significant 
benefit was seen in the primary outcome and side effects such as the 
risk of hypotension and hyperkalemia were more marked. In the 
ONTARGET trial standard clinical doses of telmisartan and rami-
pril were used. This may have given an overall   antihypertensive 
FIgure 1 | Possible pressure-dependent (A) and pressure-independent (B) effects of antihypertensive drugs on the cerebral circulation and stroke.
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Renin inhibitors
The work of Goldblatt and others (Katz et al., 1939) in the early 
1930s suggested that the link between renal ischemia provoked, for 
instance, by renal artery stenosis was renin. Building on this, the 
group of Page and Helmer at Lilly, USA provided evidence of the 
existence of an endogenous inhibitor for renin (Page and Helmer, 
1940) and this stimulated research on the use of a renin inhibitor for 
the treatment of high blood pressure. Gross and others showed that 
renin inhibitors such as the Streptomyces pentapeptide, pepstatin, 
would lower blood pressure in animal models (Lazar et al., 1972).
At this time work was being carried out simultaneously on the 
first ACEI (teprotide, the peptide from the venom of the snake, 
Bothrops jararaca) and the first ARB (the peptide analog of angi-
otensin II, saralasin). All three – pepstatin, teprotide, and sarala-
sin – are peptides presenting pharmacokinetic difficulties when 
used for daily oral treatment, as is the case for hypertension. In 
the pharmaco-chemical race to find therapeutically usable analogs, 
dose that was too high, thus producing side effects and masking 
the potentially beneficial synergism. Thus we carried out a study 
in the SHR similar to that of Menard et al. (1997) using a com-
bination of suboptimal doses, i.e., doses that did not normalize 
blood pressure when given separately (Dupuis et al., 2010). The 
0.8 mg/kg/day telmisartan plus 0.1 mg/kg/day ramipril combi-
nation (TEL8/RAM1) normalized cerebral arteriolar diameter 
(62 ± 18 μm, P < 0.05 vs. untreated SHR 42 ± 16 and normoten-
sive WKY rats 59 ± 16, n = 18 or 19 per group) and the lower limit 
of cerebral blood flow autoregulation (50 ± 10 mmHg vs. 77 ± 28 
for SHR and 53 ± 17 for WKY). TEL8/RAM1 reversed the effect 
of angiotensin II on cerebral arterioles to vasodilatation. Although 
the translation of such beneficial structural and functional effects 
in an animal model into a beneficial effect on stroke in man is 
debatable, on the basis of these results and those of Menard et al. 
(1997), quoted above, there may be a case for studying the effects 
of combinations of low doses of different inhibitors of the RAAS 
(Budzyn et al., 2010; see later).
FIgure 2 | effects of angiotensins on cerebral arteriolar diameter (from 
Vincent et al., 2005). Cumulative concentration–response curve for 
arteriolar vasoconstriction evoked by angiotensin II [(A), n = 7], and effects of 
the ACEI, captopril (10−5 M, solid bar), on vasoconstriction induced by 
angiotensin I, angiotensin II, and 5HT [(B), n = 4]. Results are expressed as 
% fall in diameter. Values are mean ± SEM. *P ≤ 0.05 vs. baseline; †P ≤ 0.05 
vs. responses induced by angiotensin I. (C) Cumulative concentration–
response curve for the arteriolar vasomotor response to angiotensin II in 
presence of the angiotensin AT1 receptor antagonist, telmisartan (10−5 M). 
Results are expressed as % change in diameter. Values are mean ± SEM; 
n = 5. *P ≤ 0.05 vs. baseline; †P ≤ 0.05 vs. responses induced by angiotensin 
II alone.
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Thus frequency of occurrence of stroke is by definition 100% 
and  other  parameters  such  as  neurological  performance  are 
measured. Inhibitors of the RAAS are active in such models. 
Thus our group has shown that the ACEI captopril will improve 
neurological performance following induced ischemia in reno-
vascular hypertensive rats (Capdeville et al., 1990). Again the 
translation of preclinical results into clinical reality is not assured. 
Recent clinical investigation into a possible beneficial effect of 
RAAS inhibition on neurological performance and cognition 
in the TRANSCEND trial (Anderson et al., 2011) came to the 
conclusion that “…blocking of the renin-angiotensin system 
had no clear effects of cognitive performance”. This question 
remains open.
RAAS inhibition in non-hypertensive patients
If it is hypothesized that inhibition of the RAAS can have beneficial 
effects that are not necessarily related to blood pressure then a 
case could be made for treating patients presenting cardiovascular 
risk, e.g., previous stroke or transient ischemic attacks, that are not 
necessarily hypertensive. This was investigated in the PROGRESS 
trial (MacMahon et al., 2001). In this trial treatment with an ACEI, 
perindopril, plus a diuretic, indapamide, reduced stroke risk in the 
non-hypertensive group.
Such observations raise another question regarding the risks 
and benefits of lowering blood pressure below classical normo-
tensive goals. In the APRIL study, normotensive rats were treated 
from the age of 6 through 30 months with a hypotensive dose of 
the ACEI, perindopril, that lowered DBP from 90 to 80 mmHg 
(Lartaud et al. 1994). Cerebrovascular dysfunction in old rats as 
evaluated by an increase in the lower limit of autoregulation of 
cerebral blood flow, was corrected by ACEI treatment. Thus in this 
animal study, life-long ACEI treatment and/or systemic arterial 
hypotension improved cerebrovascular function.
ACEI research came in first with captopril, and from then on, inter-
est waned in other forms of peptide research in the RAAS such as 
the research on renin inhibitors.
Albeit, research on renin inhibitors did not cease and in the 
1990s Novartis, Switzerland developed an orally active renin inhibi-
tor, aliskiren. The rational behind this was the same as that of the 
research of the 1960s and 1970s: a “more complete” inhibition of 
the RAAS can be obtained by blocking the first rate-limiting enzyme 
(renin) at the summit of the metabolic cascade of production of 
active peptides (angiotensins; Paulis and Unger 2010; Riccioni, 
2011). Recent clinical trials suggest that aliskiren may have benefi-
cial cardiovascular and renal effects especially in diabetes (Parving 
et al., 2008); other trials are looking at the effect of aliskiren on 
stroke (Parving et al., 2009).
It is interesting to note that in the above trials on renin inhi-
bition, dual RAAS blockade discussed previously is in fact being 
used: the renin inhibitor is added onto existing treatment with an 
ACEI or an ARB. Albeit, it has recently been concluded that for the 
time being: “…the use of dual RAAS blockade should be avoided 
unless ironclad data emerge to the contrary” (Messerli et al., 2010).
Specific aldosterone antagonists
In parallel to blocking the RAAS cascade at the summit (with a 
renin inhibitor) there may be a case for blocking the system at the 
lowest level of the cascade of active products – aldosterone. The 
RAAS presents evolutionary duality with the appearance firstly of 
a blood pressure regulatory system (using angiotensins) followed 
by the evolution of a regulatory system for sodium metabolism 
(using aldosterone; Withers, 1992). Thus although the RAAS is 
absent in cyclostomes and elasmobranchs, juxtaglomerular cells are 
present in other chondrichthyean fish and all other vertebrates. The 
macula densa, however, appears later in some amphibia and higher 
tetrapods, suggesting that it evolved at a more advanced stage. Thus 
the RAAS may have evolved as a blood pressure regulatory system 
with sodium regulation developing later.
On the basis of the argument it has been postulated that aldoster-
one acts strictly as a mineralocorticoid hormone on renal and other 
epithelia, to maintain electrolytic homeostasis (Delyani et al., 2001). 
However, already in the 1970s it was suggested that aldosterone may 
play a negative role in vascular diseases such as stroke (Brunner 
et al., 1972). More recently evidence has revealed that aldosterone 
acts also on non-epithelial vascular sites; other results have shown 
that blocking the effects of aldosterone with antagonists such as 
spironolactone diminishes cerebrovascular lesions in the rat model 
of stroke (the SHR-SP; Rocha et al., 1998). Recently our group has 
detected an inverse linear relationship between plasma aldosterone 
levels and the diameter of the cerebral arteriole in SHR (Figure 3). 
Arguments are emerging therefore, that suggest the mineralocorti-
coid receptor as a potential therapeutic target for stroke prevention 
(Osmond et al., 2008).
new theRApeutIc IndIcAtIonS And pAthwAyS
RAAS, neurological performance and cognition
In clinical trials on stroke, parameters such as occurrence, sur-
vival, and recurrence are measured. This contrasts with preclini-
cal studies. Except in some rare species such as dogs, spontaneous 
stroke rarely occurs. In most laboratory animal models cerebral 
FIgure 3 | relationship between cerebral arteriolar diameter and 
aldosterone level. Relationship between aldosterone (ALD) plasma level and 
cerebral arteriolar internal diameter in WKY-solvent (open square), WKY-ALD 
(full square), SHR-solvent (open triangle), SHR-ARB (open circle), SHR-
ARB + ALD (full circle), SHR-ACEI (open lozenge), and SHR-ACEI + ALD (full 
lozenge). Pooled n = 78. Linear regression equation: Y = −0.29X + 59; 
r2 = 0.161; degrees of freedom = 76 (P < 0.05).
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Renin–  angiotensin system blockade 
and cognitive function in patients at 
high risk of cardiovascular disease: 
There have been few clinical trials looking at the beneficial effects 
of arterial “hypotension.” In the HOT study with the calcium entry 
blocker, felodipine, lowering DBP below 90 mmHg had a benefi-
cial effect on myocardial infarction but not on stroke incidence 
(Hansson et al., 1998). The question remains open.
RAAS and large artery stiffness
With aging and cardiovascular disease such as hypertension, 
the elastic properties of large central arteries change leading to 
stiffening of the wall. This leads to a decrease in compliance and 
an increase in pulse pressure. This can be important in vascular 
beds with low flow resistance and torrential flow such as that of 
the brain (O’Rourke and Safar, 2005). Exposure of small ves-
sels to highly pulsatile pressure and flow can lead to structural 
modification and microvascular damage. This was shown for 
instance in the SHR rat by the group of Baumbach (1996) who 
found that an increase in pulse pressure – even in the absence of 
an increase in mean pressure – is enough to produce arteriolar 
wall hypertrophy.
Angiotensin I converting enzyme inhibitors may be useful in 
this context as they appear to protect the elastic fiber network of 
the arterial wall and reduced the age-related increase in wall stiff-
ness (Figure 4).
RAAS genomics and stroke
Analysis of RAAS gene polymorphisms may provide information 
for a targeted pharmaco-genomic approach to stroke prevention. 
The MOBILIZE Boston study (Hajjar et al., 2010) revealed that the 
angiotensinogen gene may be involved in cerebrovascular reactiv-
ity independently of blood pressure. Previous studies have also 
shown links between the RAAS gene polymorphisms and other 
forms of cerebrovascular dysfunction such as lacunar infarction 
(Takami et al., 2000) or cerebral white matter pathology (van Rijn 
et al., 2007) although the link to clinical stroke seems more tenu-
ous (van Rijn et al., 2007). Again the question remains open as 
to whether future research will reveal RAAS gene polymorphism 
linked to stroke that could form the basis of pharmaco-genomic 
treatment with inhibitors and antagonists of the RAAS.
concludIng RemARkS
The important issue in antihypertensive therapy is whether the 
latter prevents target organ damage in the brain, kidney, and other 
vascular beds. This review looks at the preclinical and clinical evi-
dence suggesting that drugs acting via inhibition of the RAAS have a 
cerebrovascular protective effect. Whilst a case can be made for this 
hypothesis, the latter should be strengthened by further evidence 
FIgure 4 | Increases in arterial distensibility produced by the ACeI, 
lisinopril (recalculated and redrawn from Makki et al., 1994). Four-month-
old normotensive rats were treated orally for 9 months with a low dose of 
lisinopril (0.9 mg/kg/day) or a high dose (9 mg/kg/day). ACE was inhibited in a 
dose-related fashion but the low dose treatment did not significantly modify 
systolic blood pressure (A). Arterial stiffness (judged from the relationship 
between pulse wave velocity and mean blood pressure) was reduced in a 
dose-dependent fashion (B) and this was probably due in part to a reduction in 
the loss of thickness of arterial elastic fibers with age (C).
from clinical trials. Furthermore a deeper investigation into the 
predictability of animal models of hypertension when used to test 
drugs and elaborate mechanisms is required.
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